Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499347) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499347 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499339) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499339 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499320) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499320 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499312) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499312 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499304) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499304 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-DASATINIB (DIN 02499282) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02499282 | approvedsource: Marketed | health-canada-dpd |
| Mar 3, 2021 | Lorlatinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-03 (see label) | SUPPLNDA210868 | approved | openfda |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02509261) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02509261 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02509253) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02509253 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02496860) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02496860 | approvedsource: Marketed | health-canada-dpd |
| Mar 2, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02496852) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02496852 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 25, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as HERZUMA (DIN 02506211) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02506211 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 29, 2021 | Peginterferon Beta-1a | FDA US | cancer not stated in this record | Efficacy supplement 2021-01-29 (see label) | SUPPLBLA125499 | approved | openfda |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 25, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-BENDAMUSTINE (DIN 02496895) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product… | DIN02496895 | approvedsource: Marketed | health-canada-dpd |
| Feb 25, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-BENDAMUSTINE (DIN 02496887) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product… | DIN02496887 | approvedsource: Marketed | health-canada-dpd |
| Feb 22, 2021 | Cemiplimab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-22 (see label) | SUPPLBLA761097 | approved | openfda |
| Feb 22, 2021 | Aminolevulinic Acid | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLEOLAN (DIN 02504928) under ATC L01XD04 AMINOLEVULINIC ACID. Indications are not published in the Drug Product… | DIN02504928 | approvedsource: Marketed | health-canada-dpd |
| Feb 22, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP ABIRATERONE (DIN 02502305) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02502305 | approvedsource: Marketed | health-canada-dpd |
| Feb 19, 2021 | Durvalumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-19 (see label) | SUPPLBLA761069 | approved | openfda |
| Feb 17, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-17 (see label) | SUPPLBLA761034 | approved | openfda |
| Feb 17, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-17 (see label) | SUPPLBLA761034 | approved | openfda |
| Feb 17, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-17 (see label) | SUPPLBLA761034 | approved | openfda |
| Feb 17, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-17 (see label) | SUPPLBLA761034 | approved | openfda |
| Feb 17, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-17 (see label) | SUPPLBLA761034 | approved | openfda |
| Feb 17, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-17 (see label) | SUPPLBLA761034 | approved | openfda |
| Feb 11, 2021 | Lenalidomide | EMA EU | cancer not stated in this record | Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly… | centralisedEMEA/H/C/005734 | approved | ema |
| Feb 11, 2021 | Lenalidomide | EMA EU | cancer not stated in this record | Multiple myeloma Lenalidomide Krka d.d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed… | centralisedEMEA/H/C/005729 | withdrawn | ema |
| Feb 11, 2021 | Sunitinib | EMA EU | cancer not stated in this record | Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant… | centralisedEMEA/H/C/005419 | approved | ema |
| Feb 11, 2021 | Selpercatinib | EMA EU | Tumor-agnostic | Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not… | centralisedEMEA/H/C/005375 | approved | ema |
| Feb 11, 2021 | Lenalidomide | EMA EU | cancer not stated in this record | Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple… | centralisedEMEA/H/C/005348 | approved | ema |
| Feb 11, 2021 | Tucatinib | EMA EU | Malignant Breast Neoplasm | Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally… | centralisedEMEA/H/C/005263 | approved | ema |
| Feb 9, 2021 | Cemiplimab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-09 (see label) | SUPPLBLA761097 | approved | openfda |
| Feb 9, 2021 | Cemiplimab | FDA US | cancer not stated in this record | Efficacy supplement 2021-02-09 (see label) | SUPPLBLA761097 | approved | openfda |
| Feb 8, 2021 | Moxetumomab Pasudotox | EMA EU | Hairy Cell Leukemia | Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after… | centralisedEMEA/H/C/005322 | withdrawn | ema |
| Feb 8, 2021 | Fedratinib | EMA EU | cancer not stated in this record | Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post… | centralisedEMEA/H/C/005026 | approved | ema |
| Feb 3, 2021 | Tepotinib | FDA US | Lung Non-Small Cell Carcinoma | TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring… | ORIGNDA214096 | approved | openfda |
| Feb 3, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-ABIRATERONE (DIN 02503999) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02503999 | approvedsource: Marketed | health-canada-dpd |
| Feb 3, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-ABIRATERONE (DIN 02503980) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02503980 | approvedsource: Marketed | health-canada-dpd |
| Jan 25, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ABIRATERONE FILM COATED TABLETS (DIN 02491400) under ATC L02BX03 ABIRATERONE. Indications are not published in… | DIN02491400 | approvedsource: Marketed | health-canada-dpd |
| Jan 25, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ABIRATERONE FILM COATED TABLETS (DIN 02491397) under ATC L02BX03 ABIRATERONE. Indications are not published in… | DIN02491397 | approvedsource: Marketed | health-canada-dpd |
| Jan 25, 2021 | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-MELPHALAN (DIN 02480026) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product Database… | DIN02480026 | approvedsource: Marketed | health-canada-dpd |
| Jan 22, 2021 | Nivolumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-01-22 (see label) | SUPPLBLA125554 | approved | openfda |
| Jan 22, 2021 | Cabozantinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-01-22 (see label) | SUPPLNDA208692 | approved | openfda |
| Jan 18, 2021 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NYVEPRIA (DIN 02506238) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02506238 | approvedsource: Marketed | health-canada-dpd |
| Jan 18, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-ABIRATERONE (DIN 02494132) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02494132 | approvedsource: Marketed | health-canada-dpd |
| Jan 18, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ ABIRATERONE (DIN 02486393) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02486393 | approvedsource: Marketed | health-canada-dpd |
| Jan 15, 2021 | Trastuzumab Deruxtecan | FDA US | cancer not stated in this record | Efficacy supplement 2021-01-15 (see label) | SUPPLBLA761139 | approved | openfda |
| Jan 15, 2021 | Trastuzumab Deruxtecan | FDA US | cancer not stated in this record | Efficacy supplement 2021-01-15 (see label) | SUPPLBLA761139 | approved | openfda |
| Jan 14, 2021 | Crizotinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-01-14 (see label) | SUPPLNDA202570 | approved | openfda |
| Jan 11, 2021 | Bevacizumab | EMA EU | cancer not stated in this record | Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of… | centralisedEMEA/H/C/005640 | withdrawn | ema |